Loading...
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis. PCSK9 binds to the low density lipoprotein receptor and enhances its degradation, which leads to the reduced clearance of low dens...
Saved in:
| Published in: | Eur Heart J |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Oxford University Press
2017
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5837708/ https://ncbi.nlm.nih.gov/pubmed/28637178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehx260 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|